AU2002218166A1 - Collections of repeat proteins comprising repeat modules - Google Patents

Collections of repeat proteins comprising repeat modules

Info

Publication number
AU2002218166A1
AU2002218166A1 AU2002218166A AU1816602A AU2002218166A1 AU 2002218166 A1 AU2002218166 A1 AU 2002218166A1 AU 2002218166 A AU2002218166 A AU 2002218166A AU 1816602 A AU1816602 A AU 1816602A AU 2002218166 A1 AU2002218166 A1 AU 2002218166A1
Authority
AU
Australia
Prior art keywords
repeat
collections
proteins
modules
repeat proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002218166A
Inventor
Hans Kaspar Binz
Patrick Forrer
Andreas Pluckthun
Michael Tobias Stumpp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of AU2002218166A1 publication Critical patent/AU2002218166A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1055Protein x Protein interaction, e.g. two hybrid selection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1044Preparation or screening of libraries displayed on scaffold proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1093General methods of preparing gene libraries, not provided for in other subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to collections of repeat proteins comprising repeat modules which are derived from one or more repeat units of a family of naturally occurring repeat proteins, to collections of nucleic acid molecules encoding said repeat proteins, to methods for the construction and application of such collections and to individual members of such collections.
AU2002218166A 2000-09-08 2001-09-10 Collections of repeat proteins comprising repeat modules Abandoned AU2002218166A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00119670.8 2000-09-08
EP00119670 2000-09-08
PCT/EP2001/010454 WO2002020565A2 (en) 2000-09-08 2001-09-10 Collections of repeat proteins comprising repeat modules

Publications (1)

Publication Number Publication Date
AU2002218166A1 true AU2002218166A1 (en) 2002-03-22

Family

ID=8169793

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002218166A Abandoned AU2002218166A1 (en) 2000-09-08 2001-09-10 Collections of repeat proteins comprising repeat modules

Country Status (10)

Country Link
US (4) US7417130B2 (en)
EP (2) EP2149604A1 (en)
JP (3) JP5291279B2 (en)
AT (1) ATE448301T1 (en)
AU (1) AU2002218166A1 (en)
CA (1) CA2421447C (en)
DE (1) DE60140474D1 (en)
DK (1) DK1332209T3 (en)
ES (1) ES2335861T3 (en)
WO (1) WO2002020565A2 (en)

Families Citing this family (395)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2006028480A1 (en) * 2004-09-07 2006-03-16 Clonex Development, Inc. Cell lines for use in increasing protein yield form a cell culture
WO2006129828A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Target substance capturing molecule
JP5322653B2 (en) 2005-11-28 2013-10-23 ザイモジェネティクス, インコーポレイテッド IL-21 antagonist
AU2015203464B2 (en) * 2006-02-13 2017-08-10 Monsanto Technology Llc Plant chimeric binding polypeptides for universal molecular recognition
AR059448A1 (en) 2006-02-13 2008-04-09 Divergence Inc UNION VEGETABLE CHEMICAL POLIPEPTIDES FOR UNIVERSAL MOLECULAR RECOGNITION
AU2013201171B2 (en) * 2006-02-13 2016-01-21 Monsanto Technology Llc Plant chimeric binding polypeptides for universal molecular recognition
US7897568B2 (en) 2006-03-03 2011-03-01 Vinay K. Singh Compositions for treatment of cancer
MX2008013705A (en) 2006-04-28 2008-11-06 Esbatech Ag Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk.
EA200970250A1 (en) 2006-09-05 2010-02-26 Медарекс, Инк. ANTIBODIES TO BONE MORPHOGENETIC PROTEINS AND THEIR RECEPTORS AND METHODS OF THEIR APPLICATION
KR20150065959A (en) 2006-10-02 2015-06-15 메다렉스, 엘.엘.시. Human antibodies that bind cxcr4 and uses thereof
JP5207222B2 (en) * 2006-11-17 2013-06-12 独立行政法人農業生物資源研究所 Protein production method using repetitive sequence such as leucine rich repeat (LRR) sequence
MX2009005466A (en) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir.
KR101552735B1 (en) 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 22 human antibodies that bind cd22 and uses thereof
CL2007003622A1 (en) 2006-12-13 2009-08-07 Medarex Inc Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
EP2097534A4 (en) 2006-12-14 2010-05-12 Medarex Inc Human antibodies that bind cd70 and uses thereof
EP3202786A3 (en) 2007-03-12 2017-10-11 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
CA2682350A1 (en) * 2007-04-11 2008-10-23 The Jackson Laboratory Diagnosis and treatment of diseases caused by misfolded proteins
DK2208737T3 (en) 2007-05-03 2017-09-18 Lysomab Gmbh Complement factor H-derived short-consensus repeat antibody constructs
BRPI0812400A2 (en) 2007-06-05 2014-10-29 Univ Yale UNIT, HYBRIDOMA, PHARMACEUTICAL COMPOSITION, METHOD FOR IDENTIFYING A UNIT, ANTIBODY ISOLATED TO A SAME ANTIGEN CONNECTION UNIT, PEPTIDES MOLECULE, AND UNIT USE.
ES2532725T3 (en) 2007-06-25 2015-03-31 Esbatech, An Alcon Biomedical Research Unit Llc Genetic engineering modification based on sequence and optimization of single chain antibodies
MX2009013328A (en) 2007-06-25 2010-06-02 Esbatech An Alcon Biomedical R Methods of modifying antibodies, and modified antibodies with improved functional properties.
EP2198022B1 (en) * 2007-09-24 2024-03-06 University Of Zurich Designed armadillo repeat proteins
EA023031B1 (en) 2007-11-30 2016-04-29 Глаксо Груп Лимитед Antigen-binding construct and use thereof
AU2008364115B2 (en) 2007-12-07 2013-11-21 Zymogenetics, Inc. Anti-human IL-21 monoclonal antibodies
WO2009100990A1 (en) * 2008-02-13 2009-08-20 Dsm Ip Assets B.V. Process for the production of a peptide
MX2010008874A (en) 2008-02-14 2010-09-22 Bristol Myers Squibb Co Targeted therapeutics based on engineered proteins that bind egfr.
US20110262964A1 (en) * 2008-03-19 2011-10-27 Hugues Bedouelle Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
EP2103936A1 (en) * 2008-03-19 2009-09-23 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat module and methods of their design and use
CN102056946A (en) 2008-04-11 2011-05-11 中外制药株式会社 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
UY31808A (en) 2008-05-06 2009-12-14 Glaxo Group Ltd ENCAPSULATION OF BIOLOGICALLY ACTIVE AGENTS
JP2011520961A (en) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー Scaffold domain protein based on multivalent fibronectin
LT3241843T (en) 2008-06-25 2021-09-27 Novartis Ag Solubility optimization of immunobinders
CN102177438A (en) 2008-07-25 2011-09-07 理查德·W·瓦格纳 protein screening method
EP2326351B1 (en) 2008-08-19 2017-12-27 Nektar Therapeutics Conjugates of small-interfering nucleic acids
CN107011425B (en) * 2008-11-03 2021-01-01 分子组合公司 Binding proteins that inhibit VEGF-A receptor interactions
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
EP2389394A2 (en) 2009-01-21 2011-11-30 Oxford Biotherapeutics Ltd. Pta089 protein
CA2753332A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
US20110305692A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Antigen-binding contructs
CN102239181A (en) * 2009-02-24 2011-11-09 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 Methods for identifying immunobinders of cell-surface antigens
WO2010097394A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
US8420084B2 (en) 2009-03-05 2013-04-16 Medarex, Inc. Fully human antibodies specific to CADM1
MX2011011075A (en) 2009-04-20 2011-11-04 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17.
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
JP5426026B2 (en) 2009-07-28 2014-02-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Non-invasive in vivo optical imaging method
EP2470569A1 (en) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antibodies against epha10
EP2496605A1 (en) 2009-11-02 2012-09-12 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
TW201120210A (en) 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
WO2011072266A2 (en) 2009-12-11 2011-06-16 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
SG182590A1 (en) 2010-01-28 2012-08-30 Glaxo Group Ltd Cd127 binding proteins
BR112012019902A2 (en) 2010-02-10 2019-09-24 Novartis Ag "method and compounds for muscle growth"
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
AU2011230537C1 (en) 2010-03-26 2018-08-02 Trustees Of Dartmouth College Vista regulatory T cell mediator protein, vista binding agents and use thereof
TWI667257B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
EP2563380B1 (en) 2010-04-26 2018-05-30 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
EP2563381B1 (en) 2010-04-27 2017-08-09 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
WO2011150279A2 (en) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
JP6008838B2 (en) 2010-04-29 2016-10-19 エータイアー ファーマ, インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of asparaginyl tRNA synthetase
US9034320B2 (en) 2010-04-29 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
AR081361A1 (en) 2010-04-30 2012-08-29 Molecular Partners Ag MODIFIED UNION PROTEINS THAT INHIBIT THE RECEPTOR INTERACTION OF THE VASCULAR ENDOTELIAL GROWTH FACTOR FROM GLICOPROTEIN TO VEGF-A
EP2566515B1 (en) 2010-05-03 2017-08-02 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
WO2011140132A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
CN103140233B (en) 2010-05-03 2017-04-05 Atyr 医药公司 Treatment, diagnosis and the discovery of antibody compositions related to the protein fragments of methionyl-tRNA synthetase
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
BR112012028006A2 (en) 2010-05-07 2016-08-02 Hoffmann La Roche immunohistochemistry (ihq) method, use of a therapeutically active binding domain, kit and binding domain
CA3090304A1 (en) 2010-05-13 2011-11-17 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
TW201210612A (en) 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
EP3560962A1 (en) 2010-07-09 2019-10-30 Bioverativ Therapeutics Inc. Processable single chain molecules and polypeptides made using same
WO2012021247A2 (en) 2010-07-12 2012-02-16 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
SG188666A1 (en) 2010-09-30 2013-05-31 Agency Science Tech & Res Methods and reagents for detection and treatment of esophageal metaplasia
AR083495A1 (en) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit STABLE AND SOLUBLE ANTIBODIES
WO2012066058A1 (en) 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
TWI629355B (en) 2010-11-17 2018-07-11 中外製藥股份有限公司 Multispecific antigen-binding molecule capable of replacing blood coagulation factor VIII
TR201810773T4 (en) 2010-11-23 2018-08-27 Glaxo Group Ltd Oncostatin (osm) antigen binding proteins.
EP2853542A1 (en) 2010-11-24 2015-04-01 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
RU2636552C2 (en) 2010-11-26 2017-11-23 Молекьюлер Партнерс Аг Improved n-terminal capping modules for constructed ankyrin repeat proteins
EP4231014A3 (en) 2010-11-30 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP3539991A1 (en) 2011-01-07 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
US9499592B2 (en) * 2011-01-26 2016-11-22 President And Fellows Of Harvard College Transcription activator-like effectors
CA2825919C (en) 2011-02-15 2018-05-01 Immunogen, Inc. Methods of preparation of conjugates
BR112013021526B1 (en) 2011-02-25 2021-09-21 Chugai Seiyaku Kabushiki Kaisha VARIANT POLYPEPTIDE, METHODS FOR MAINTAINING OR DECREASE BINDING ACTIVITIES TO FCGRIIA (TYPE R) AND FCGRIIA (TYPE H) AND INCREASING FCGRIIB BINDING ACTIVITY OF A POLYPEPTIDE AND FOR SUPPRESSING THE PRODUCTION OF AN ANTIBODY AGAINST A POLYENDENDOPEPTIDE ANTIBODY FC, METHODS FOR THE PRODUCTION OF SUCH POLYPEPTIDE WITH MAINTAINED OR DECREASED AND INCREASED BINDING ACTIVITIES AND FOR THE SUPPRESSED PRODUCTION OF AN ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE OF A POLYPEPTIDE
EP3825325A3 (en) 2011-03-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
RU2016147206A (en) 2011-04-15 2018-10-19 Компуджен Лтд. Polypeptides and polynucleotides and their use for the treatment of immunological disorders and cancer
BR112013027766A2 (en) 2011-04-29 2016-11-29 Janssen Biotech Inc il4 / il13 binding repeat proteins and uses
RU2640254C2 (en) 2011-05-06 2017-12-27 Нексвет Австралия Пти Лтд Antibodies against nerve growth factor and methods for their production and application
ES2905682T3 (en) 2011-05-06 2022-04-11 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparation and use thereof
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
RU2640252C2 (en) 2011-05-06 2017-12-27 Нексвет Австралия Пти Лтд Antibodies against nerve growth factor and methods for their production and application
EA028220B1 (en) 2011-05-27 2017-10-31 Глаксо Груп Лимитед Immunoconjugate comprising bcma (cd269/tnfrsf17) binding protein, medical use thereof and pharmaceutical composition
DK2717898T3 (en) 2011-06-10 2019-03-25 Bioverativ Therapeutics Inc COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF
MX343580B (en) 2011-06-13 2016-11-10 Csl Ltd Antibodies against g-csfr and uses thereof.
CN103648532A (en) 2011-06-21 2014-03-19 伊缪诺金公司 Novel maytansinoid derivatives with peptide linker and conjugates thereof
GEP201706667B (en) 2011-06-28 2017-05-25 Berlin - Chemie Ag Antibodies to adp-ribosyl cyclase 2
JP6113721B2 (en) 2011-06-28 2017-04-12 オックスフォード ビオトヘラペウトイクス エルティーディー. Therapeutic and diagnostic targets
CA2839539C (en) 2011-06-30 2021-06-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
AU2012317418B2 (en) 2011-09-30 2017-09-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting elimination of antigens
CN110680920A (en) 2011-09-30 2020-01-14 中外制药株式会社 Antigen binding molecules that induce an immune response against a target antigen
TW201326209A (en) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
IN2014CN03066A (en) 2011-09-30 2015-08-07 Chugai Pharmaceutical Co Ltd
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
EP3617313A1 (en) 2011-10-05 2020-03-04 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
EP2771351B1 (en) 2011-10-28 2017-06-14 Patrys Limited Pat-lm1 epitopes and methods for using same
US20130156766A1 (en) 2011-11-15 2013-06-20 Allergan, Inc. Treatment of dry age related macular degeneration
SG10201609301QA (en) 2011-11-30 2016-12-29 Chugai Pharmaceutical Co Ltd Drug containing carrier into cell for forming immune complex
EP2612916A1 (en) 2012-01-09 2013-07-10 Universität Zürich Cellular high throughput encapsulation for screening or selection
PL2802606T3 (en) 2012-01-10 2018-09-28 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
US20150210763A1 (en) 2012-02-09 2015-07-30 Chugai Seiyaku Kabushiki Kaisha MODIFIED Fc REGION OF ANTIBODY
SG11201404850SA (en) 2012-02-13 2014-09-26 Agency Science Tech & Res IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
CA2864300A1 (en) 2012-02-16 2013-08-22 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
WO2013121038A1 (en) 2012-02-17 2013-08-22 Centro Nacional De Investigaciones Oncológicas Mammalian homologues of flower, their use in cancer diagnostics, prevention and treatment
DK2818183T3 (en) 2012-02-24 2020-06-15 Chugai Pharmaceutical Co Ltd Antigen-binding molecule to promote the disappearance of antigen by Fc RIIB
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
PL2846836T3 (en) 2012-05-07 2020-01-31 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2013180201A1 (en) 2012-05-30 2013-12-05 中外製薬株式会社 Antigen-binding molecule for eliminating aggregated antigens
SG11201407963PA (en) 2012-05-30 2015-01-29 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule
JP6628966B2 (en) 2012-06-14 2020-01-15 中外製薬株式会社 Antigen binding molecule containing an altered Fc region
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
SG11201408196RA (en) 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
AR091774A1 (en) * 2012-07-16 2015-02-25 Dow Agrosciences Llc PROCESS FOR THE DESIGN OF REPEATED, LONG, DIVERGENT DNA SEQUENCES OF OPTIMIZED CODONS
EP2692731A1 (en) * 2012-07-31 2014-02-05 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Recombinant Adeno-Associated virus (AAV) vector particles displaying high-affinity ligands for cell-type specific gene delivery
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd MOUSE Fc RII-SPECIFIC Fc ANTIBODY
WO2014030728A1 (en) 2012-08-24 2014-02-27 中外製薬株式会社 Fcγriib-specific fc region variant
CN105246507B (en) 2012-09-07 2019-01-25 达特茅斯大学理事会 VISTA regulator for diagnosing and treating cancer
RU2683933C2 (en) 2012-09-28 2019-04-03 Чугаи Сейяку Кабусики Кайся Method for evaluating reaction of blood coagulation
AU2013331763B2 (en) 2012-10-15 2018-02-15 Universitat Zurich Bispecific HER2 ligands for cancer therapy
EP2719706A1 (en) 2012-10-15 2014-04-16 Universität Zürich Bispecific HER2 ligands for cancer therapy
AU2013343667A1 (en) 2012-11-08 2015-04-02 F. Hoffmann-La Roche Ag HER3 antigen binding proteins binding to the beta-hairpin of HER3
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP2935589A1 (en) 2012-12-18 2015-10-28 Novartis AG Compositions and methods that utilize a peptide tag that binds to hyaluronan
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
KR20150122761A (en) 2013-02-26 2015-11-02 로슈 글리카트 아게 Bispecific t cell activating antigen binding molecules
WO2014133855A1 (en) 2013-02-28 2014-09-04 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
EP2961435B1 (en) 2013-02-28 2019-05-01 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP3566750A3 (en) 2013-02-28 2020-04-08 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
TWI788044B (en) 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 Factor ix polypeptide formulations
CN105246914B (en) 2013-04-02 2021-08-27 中外制药株式会社 Fc region variants
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
EP3004152B1 (en) * 2013-05-31 2020-09-30 Molecular Partners AG Designed ankyrin repeat proteins binding to hepatocyte growth factor
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
KR102236367B1 (en) 2013-07-26 2021-04-05 삼성전자주식회사 Bispecific chimeric proteins with DARPins
AU2014329437B2 (en) 2013-10-06 2018-10-18 F. Hoffmann-La Roche Ag Modified Pseudomonas exotoxin A
HUE047910T2 (en) 2013-11-05 2020-05-28 Allergan Inc Method of treating conditions of the eye with an anti-vegf darpin
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
CN105980557B (en) 2013-12-04 2020-04-07 中外制药株式会社 Antigen binding molecules with variable antigen binding capacity depending on concentration of compound and libraries thereof
KR102466794B1 (en) 2013-12-18 2022-11-11 씨에스엘 리미티드 Method of treating wounds
CA3190821A1 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR20150092637A (en) 2014-02-05 2015-08-13 삼성전자주식회사 p16 protein variant and composition for preventing or treating a cancer containing the same
KR20150092638A (en) 2014-02-05 2015-08-13 삼성전자주식회사 p15 protein variant and composition for preventing or treating a cancer containing the same
KR20150097304A (en) 2014-02-18 2015-08-26 삼성전자주식회사 Anti-EGFR/Anti-HER2 Bispecific Antibodies With Anti-EGFR DARPins
CA2951885C (en) 2014-06-11 2023-07-04 Kathy A. Green Use of vista agonists and antagonists to suppress or enhance humoral immunity
TW201625299A (en) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
EP3160990A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
EP3626822A1 (en) 2014-08-15 2020-03-25 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
JP6606545B2 (en) 2014-09-03 2019-11-13 イミュノジェン・インコーポレーテッド Cytotoxic benzodiazepine derivatives
JP2017527562A (en) 2014-09-03 2017-09-21 イミュノジェン・インコーポレーテッド Cytotoxic benzodiazepine derivatives
CN106922129B (en) 2014-10-01 2024-02-20 免疫医疗有限责任公司 Methods of conjugating polypeptides
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
IL282922B (en) 2014-11-14 2022-08-01 Hoffmann La Roche Antigen binding molecules comprising a tnf family ligand trimer
CN107405398A (en) 2014-12-05 2017-11-28 伊穆奈克斯特股份有限公司 VSIG8 is identified as presumption VISTA acceptors and its to produce the purposes of VISTA/VSIG8 activators and antagonist
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN116869964B (en) 2014-12-24 2024-10-18 耐克西缪恩有限公司 Nanoparticle compositions and methods for immunotherapy
MX2017008978A (en) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof.
ES2953482T3 (en) 2015-04-02 2023-11-13 Molecular Partners Ag Ankyrin repeat domains designed with binding specificity for serum albumin
CA2978038A1 (en) 2015-04-17 2016-10-20 F. Hoffmann-La Roche Ag Combination therapy with coagulation factors and multispecific antibodies
CN107921132B (en) 2015-06-04 2021-05-07 圣拉斐尔医院有限公司 Diabetes and IGFBP3/TMEM219 axis inhibitors
EA201792669A1 (en) 2015-06-04 2018-06-29 Оспедале Сан Раффаэле Срл IGFBP3 AND ITS APPLICATION
KR101713944B1 (en) * 2015-06-19 2017-03-09 한국과학기술원 Novel polypeptide binding with human vascular endothelial growth factor and Uses Thereof
MX2017016647A (en) 2015-06-24 2019-04-25 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments.
BR112018001955B1 (en) 2015-08-03 2021-05-11 Engmab Sárl monoclonal antibody that binds to human b cells (bcma), pharmaceutical composition and its use
EP3350202A1 (en) 2015-09-18 2018-07-25 Chugai Seiyaku Kabushiki Kaisha Il-8-binding antibodies and uses thereof
AR106188A1 (en) 2015-10-01 2017-12-20 Hoffmann La Roche ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
CA2992863A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
CN108137699B (en) 2015-10-02 2022-05-27 豪夫迈·罗氏有限公司 Bispecific antibodies specific for PD1 and TIM3
MY193013A (en) 2015-10-07 2022-09-22 Hoffmann La Roche Bispecific antibodies with tetravalency for a costimulatory tnf receptor
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
CA3005284A1 (en) 2015-11-19 2017-05-26 Asclepix Therapeutics, Llc. Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
EP3383422B1 (en) 2015-12-02 2021-08-11 Fred Hutchinson Cancer Research Center Circular tandem repeat proteins
EP4421094A3 (en) 2016-02-05 2024-11-06 Orionis Biosciences BV Targeted therapeutic agents and uses thereof
TW202216201A (en) 2016-02-12 2022-05-01 比利時商楊森製藥公司 Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP2019507762A (en) 2016-03-07 2019-03-22 ブイアイビー ブイゼットダブリュー CD20 binding single domain antibody
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
CA3020848A1 (en) 2016-04-15 2017-10-19 Janssen Pharmaceuticals, Inc. Anti-human vista antibodies and use thereof
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
CN109071652B (en) 2016-05-11 2022-09-23 豪夫迈·罗氏有限公司 Antigen binding molecules comprising TNF family ligand trimers and tenascin binding modules
JP7105200B2 (en) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ Targeted mutant interferon-beta and its uses
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
WO2018011405A1 (en) 2016-07-15 2018-01-18 Universität Zürich Il-13ralpha1 antibodies for use in treatment of atopic inflammation, sepsis and neutropenia
CN109661241A (en) 2016-09-06 2019-04-19 中外制药株式会社 Use the method for identification plasma thromboplastin component and/or the bispecific antibody of activated clotting factor IX and Stuart factor and/or activated clotting factor X
JP2020501508A (en) 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド Multimers, tetramers and octamers
AR109680A1 (en) 2016-09-22 2019-01-09 Molecular Partners Ag RECOMBINANT PROTEINS AND THEIR USES
EP3515948A4 (en) 2016-09-23 2020-04-08 CSL Limited Coagulation factor binding proteins and uses thereof
MX2019003895A (en) 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compounds and methods for activating tie2 signaling.
CN110114368B (en) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 Targeted mutant interferon-gamma and uses thereof
MX2019004621A (en) 2016-11-02 2019-11-28 Engmab Sarl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma.
KR102221364B1 (en) 2016-11-21 2021-03-04 쿠레아브 게엠베하 Anti-GP73   Antibody   and   Immunoconjugate
KR20230073346A (en) 2016-11-28 2023-05-25 추가이 세이야쿠 가부시키가이샤 Ligand-binding molecule having adjustable ligand binding activity
IL266860B2 (en) 2016-11-28 2024-09-01 Chugai Pharmaceutical Co Ltd Polypeptide comprising antigen binding domain and carrying moiety
JP7125400B2 (en) 2016-12-19 2022-08-24 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Combination therapy with targeted 4-1BB (CD137) agonists
JP7247091B2 (en) 2016-12-20 2023-03-28 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Combination therapy with anti-CD20/anti-CD3 bispecific antibody and 4-1BB (CD137) agonist
BR112019013189A2 (en) 2017-01-03 2019-12-10 Hoffmann La Roche bispecific antigen binding molecules, polynucleotide, host cell, bispecific antigen binding molecule production method, pharmaceutical composition, use, methods for inhibiting tumor cell growth in an individual and for treating cancer or an infectious disease
EP3576765A4 (en) 2017-02-06 2020-12-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
KR102642385B1 (en) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 Targeted chimeric proteins and uses thereof
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
WO2018160539A1 (en) 2017-02-28 2018-09-07 Immunogen, Inc. Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
EP3601346A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
KR102687774B1 (en) 2017-03-31 2024-07-24 고리츠다이가쿠호징 나라켕리츠 이카다이가쿠 A pharmaceutical composition used for the prevention and/or treatment of blood coagulation factor IX abnormality, comprising a multispecific antigen-binding molecule that replaces the function of blood coagulation factor VIII
MX2019011907A (en) 2017-04-04 2020-01-09 Hoffmann La Roche Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap.
MX2019011910A (en) 2017-04-05 2020-01-09 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3.
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
AR111963A1 (en) 2017-05-26 2019-09-04 Univ California METHOD AND MOLECULES
WO2019028427A1 (en) 2017-08-03 2019-02-07 Asclepix Therapeutics, Llc. Methods for identifying and preparing pharmaceutical agents for activating tie2 receptor
JP6496095B1 (en) 2017-09-29 2019-04-03 中外製薬株式会社 Multispecific antigen-binding molecule having blood coagulation factor VIII (FVIII) cofactor function alternative activity and pharmaceutical preparation containing the molecule as an active ingredient
US12059476B2 (en) 2017-10-10 2024-08-13 The Johns Hopkins University Biodegradable biomimetic particles
US11466073B2 (en) 2017-10-18 2022-10-11 Csl Limited Human serum albumin variants and uses thereof
JP2021501162A (en) 2017-11-01 2021-01-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Combination therapy with targeted OX40 agonist
EP3703746A1 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Novel tnf family ligand trimer-containing antigen binding molecules
KR20200079492A (en) 2017-11-01 2020-07-03 에프. 호프만-라 로슈 아게 Bispecific 2+1 connector
CA3083346A1 (en) 2017-11-28 2019-06-06 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand-binding activity
TW202348632A (en) 2017-11-28 2023-12-16 日商中外製藥股份有限公司 Polypeptide comprising antigen-binding domain and carrying part
CA3081770A1 (en) 2017-11-29 2019-06-06 Csl Limited Method of treating or preventing ischemia-reperfusion injury
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
TW202413360A (en) 2017-12-28 2024-04-01 美商伊繆諾金公司 Benzodiazepine derivatives
JP7426724B2 (en) 2018-01-05 2024-02-02 エイシー イミューン ソシエテ アノニム Misfolded TDP-43 binding molecule
EP3746470A1 (en) 2018-01-31 2020-12-09 F. Hoffmann-La Roche AG Stabilized immunoglobulin domains
CN111655730A (en) 2018-01-31 2020-09-11 豪夫迈·罗氏有限公司 Bispecific antibodies comprising an antigen binding site that binds to LAG3
EP3749295A4 (en) 2018-02-05 2022-04-27 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
US11591399B2 (en) 2018-02-14 2023-02-28 Abba Therapeutics Ag Anti-human PD-L2 antibodies
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
TWI841551B (en) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 Combination therapy with targeted 4-1bb (cd137) agonists
MX2020009468A (en) 2018-03-13 2020-10-22 Hoffmann La Roche Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies.
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
WO2019180243A1 (en) 2018-03-22 2019-09-26 Charité-Universitätsmedizin Berlin Crispr associated protein reactive t cell immunity
AR114284A1 (en) 2018-04-13 2020-08-12 Hoffmann La Roche HER2 TARGETING ANTIGEN BINDING MOLECULES COMPOSING 4-1BBL
CA3097648A1 (en) * 2018-04-18 2019-10-24 Altius Institute For Biomedical Sciences Animal pathogen-derived polypeptides and uses thereof for genetic engineering
WO2019229701A2 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
US20210253723A1 (en) 2018-06-15 2021-08-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
JPWO2019244973A1 (en) 2018-06-20 2021-07-08 中外製薬株式会社 Methods and Compositions for Activating the Immune Response to Target Cells
JP2021528988A (en) 2018-07-04 2021-10-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト New bispecific agonist 4-1BB antigen-binding molecule
AU2019318031A1 (en) 2018-08-10 2021-02-25 Chugai Seiyaku Kabushiki Kaisha Anti-CD137 antigen-binding molecule and utilization thereof
CN112955468B (en) 2018-10-01 2024-08-09 豪夫迈·罗氏有限公司 Bispecific antigen binding molecules comprising anti-FAP clone 212
CN112654641A (en) 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 Bispecific antigen binding molecules with trivalent binding to CD40
EP3632929A1 (en) 2018-10-02 2020-04-08 Ospedale San Raffaele S.r.l. Antibodies and uses thereof
KR20210075080A (en) 2018-10-08 2021-06-22 유니베르시태트 취리히 HER2-binding tetrameric polypeptide
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
US20220017433A1 (en) 2018-11-21 2022-01-20 Universität Zürich Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
UA128001C2 (en) 2018-12-21 2024-03-06 Ф. Хоффманн-Ля Рош Аг Tumor-targeted agonistic cd28 antigen binding molecules
CN113286822A (en) 2018-12-21 2021-08-20 豪夫迈·罗氏有限公司 Tumor-targeting hyperactive CD28 antigen binding molecules
EP3677911A3 (en) 2019-01-03 2020-07-29 Universität Basel Use of non-agonist ligands for suppression of metastasis
EP3908274A1 (en) 2019-01-11 2021-11-17 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2020168059A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
CA3129317A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
US20220155309A1 (en) 2019-02-27 2022-05-19 National University Corporation Tokyo Medical And Dental University Fusion protein of antigen-binding protein and fluorescent protein or fluorescence-labeled tag protein
AU2020235455A1 (en) 2019-03-08 2021-10-28 Oxford Genetics Limited Method of selecting for antibodies
GB201903233D0 (en) 2019-03-08 2019-04-24 Oxford Genetics Ltd Method of selecting for antibodies
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
EP3943108A4 (en) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
AU2020240310A1 (en) 2019-03-21 2021-10-07 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
TW202102506A (en) 2019-03-29 2021-01-16 美商伊繆諾金公司 Benzodiazepine derivatives
EP3950938A4 (en) 2019-04-02 2023-01-18 Chugai Seiyaku Kabushiki Kaisha Method of introducing target-specific foreign gene
US20220178926A1 (en) 2019-04-10 2022-06-09 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
WO2020208049A1 (en) 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising lipocalin muteins
CN114206444A (en) 2019-04-18 2022-03-18 Ac免疫有限公司 Novel molecules for therapy and diagnosis
KR20220027828A (en) 2019-04-26 2022-03-08 이뮤노젠 아이엔씨 camptothecin derivatives
KR20220010743A (en) 2019-05-21 2022-01-26 노파르티스 아게 Trispecific binding molecules to BCMA and uses thereof
AU2020279974B2 (en) 2019-05-21 2024-12-19 Novartis Ag CD19 binding molecules and uses thereof
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
CN114008073A (en) 2019-05-23 2022-02-01 Ac免疫有限公司 anti-TDP-43 binding molecules and uses thereof
MX2021014649A (en) 2019-06-04 2022-01-06 Molecular Partners Ag Designed ankyrin repeat domain with improved stability.
WO2020245173A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant fap binding proteins and their use
AR119080A1 (en) 2019-06-04 2021-11-24 Molecular Partners Ag MULTISPECIFIC PROTEINS
WO2020245175A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant 4-1bb binding proteins and their use
JPWO2020246567A1 (en) 2019-06-05 2020-12-10
WO2020246563A1 (en) 2019-06-05 2020-12-10 中外製薬株式会社 Antibody cleavage site-binding molecule
US20220253669A1 (en) 2019-06-07 2022-08-11 Chugai Seiyaku Kabushiki Kaisha Information processing system, information processing method, program, and method for producing antigen-binding molecule or protein
US20220324893A1 (en) 2019-06-18 2022-10-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Site-specific, kinetically inert conjugation of labels and/or carriers to target molecules such as his-tagged proteins via metal complex reagents
MX2021015888A (en) 2019-06-26 2022-03-22 Hoffmann La Roche Fusion of an antibody binding cea and 4-1bbl.
CN114531878A (en) 2019-06-27 2022-05-24 豪夫迈·罗氏有限公司 Novel ICOS antibodies and tumor-targeted antigen-binding molecules comprising same
WO2021044050A1 (en) 2019-09-05 2021-03-11 Genome Biologics Ug Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure
KR20220100611A (en) 2019-11-15 2022-07-15 엔테라 에스.알.엘. TMEM219 antibody and therapeutic use thereof
WO2021099484A1 (en) 2019-11-20 2021-05-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Archaeal peptide recombinase – a novel peptide ligating enzyme
KR102416078B1 (en) 2019-11-20 2022-07-01 추가이 세이야쿠 가부시키가이샤 Antibody-containing formulations
WO2021099574A1 (en) 2019-11-21 2021-05-27 Enthera S.R.L. Igfbp3 antibodies and therapeutic uses thereof
CN115666594A (en) 2019-11-29 2023-01-31 苏州诺沃泰医药科技有限公司 Application of CART cells in preparation of medicine for treating cancer
BR112022011177A2 (en) 2019-12-11 2022-09-27 Molecular Partners Ag ANCHYRIN REPETITION DOMAINS DESIGNED WITH ALTERED SURFACE RESIDUES
CA3161319A1 (en) 2019-12-11 2021-06-17 Victor LEVITSKY Recombinant peptide-mhc complex binding proteins and their generation and use
WO2021122813A1 (en) 2019-12-16 2021-06-24 Universität Basel Angiogenesis promoting agents for prevention of metastatic cancer
TW202144395A (en) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 Anti-CD137 antigen-binding molecule for use in cancer treatment
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
WO2021176008A1 (en) 2020-03-04 2021-09-10 Cornell University Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
US20230128499A1 (en) 2020-03-27 2023-04-27 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
AR121706A1 (en) 2020-04-01 2022-06-29 Hoffmann La Roche OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES
US20230151118A1 (en) 2020-04-06 2023-05-18 Universität Zürich Artc1 ligands for cancer treatment
EP4146691A1 (en) 2020-05-06 2023-03-15 Molecular Partners AG Novel ankyrin repeat binding proteins and their uses
EP4149959A1 (en) 2020-05-14 2023-03-22 Molecular Partners AG Multispecific proteins
CA3178478A1 (en) 2020-05-14 2021-11-18 Valerie Perrine Calabro Recombinant cd40 binding proteins and their use
IL298287A (en) 2020-05-19 2023-01-01 Boehringer Ingelheim Int Binding molecules for the treatment of cancer
WO2021239844A1 (en) 2020-05-27 2021-12-02 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes
WO2021239999A1 (en) 2020-05-28 2021-12-02 Universität Zürich Il-12 pd-l1 ligand fusion protein
EP4168448A1 (en) 2020-06-23 2023-04-26 F. Hoffmann-La Roche AG Agonistic cd28 antigen binding molecules targeting her2
CN115916830A (en) 2020-06-25 2023-04-04 豪夫迈·罗氏有限公司 anti-CD 3/anti-CD 28 bispecific antigen binding molecules
TW202220677A (en) 2020-07-31 2022-06-01 日商中外製藥股份有限公司 Pharmaceutical composition comprising cell expressing chimeric receptor
WO2022029306A1 (en) 2020-08-07 2022-02-10 F. Hoffmann-La Roche Ag Method for producing protein compositions
AR123254A1 (en) 2020-08-14 2022-11-16 Ac Immune Sa HUMANIZED ANTI-TDP-43 BINDING MOLECULES AND THEIR USES
WO2022038193A1 (en) 2020-08-18 2022-02-24 Universität Zürich A cd25-biased anti-il-2 antibody
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
EP4204448A2 (en) 2020-08-27 2023-07-05 cureab GmbH Anti-golph2 antibodies for macrophage and dendritic cell differentiation
EP4209227A4 (en) 2020-09-01 2024-05-29 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
EP4228702A1 (en) 2020-10-15 2023-08-23 F. Hoffmann-La Roche AG Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery
EP4229082A1 (en) 2020-10-16 2023-08-23 AC Immune SA Antibodies binding to alpha-synuclein for therapy and diagnosis
CN112230587B (en) * 2020-10-29 2021-08-10 中国民用航空总局第二研究所 Instrument landing system same-frequency different-call operation monitoring system and method
CN116390933A (en) 2020-11-06 2023-07-04 诺华股份有限公司 anti-CD 19 agents and B cell targeting agent combination therapies for the treatment of B cell malignancies
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
EP4244254A1 (en) 2020-11-16 2023-09-20 F. Hoffmann-La Roche AG Combination therapy with fap-targeted cd40 agonists
US20240018265A1 (en) 2020-12-11 2024-01-18 Friedrich Miescher Institute For Biomedical Research Hdac6 binding proteins and their anti-viral use
CA3202296A1 (en) 2020-12-16 2022-06-23 Sebastian Grimm Recombinant cd3 binding proteins and their use
AU2021403833A1 (en) 2020-12-16 2023-07-27 Molecular Partners Ag Novel slow-release prodrugs
CA3207090A1 (en) 2021-01-06 2022-07-14 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
WO2022169825A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
EP4291901A1 (en) 2021-02-11 2023-12-20 Universität Zürich Use of markers found on lymph node metastatic samples for the prognosis of breast cancer
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
EP4304730A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Novel darpin based cd33 engagers
CA3211368A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
EP4305063A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Protease cleavable prodrugs
US11834504B2 (en) 2021-03-09 2023-12-05 Molecular Partners Ag DARPin based multi-specific t-cell engagers
WO2022219185A1 (en) 2021-04-16 2022-10-20 Athebio Ag N-terminal capping modules of ankyrin repeat domains
WO2022244838A1 (en) 2021-05-19 2022-11-24 中外製薬株式会社 Method for predicting in vivo pharmacokinetics of molecule
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
AR126009A1 (en) 2021-06-02 2023-08-30 Hoffmann La Roche CD28 ANTIGEN-BINDING AGONIST MOLECULES THAT TARGET EPCAM
BR112023026966A2 (en) 2021-07-02 2024-03-12 Hoffmann La Roche METHODS FOR TREATING AN INDIVIDUAL WITH MELANOMA, FOR ACHIEVING A CLINICAL RESPONSE, FOR TREATING AN INDIVIDUAL WITH NON-HODGKIN LYMPHOMA, FOR TREATING A POPULATION OF INDIVIDUALS WITH NON-HODGKIN LYMPHOMA, AND FOR TREATING AN INDIVIDUAL WITH METASTATIC COLORECTAL CANCER
AU2022323540A1 (en) 2021-08-05 2024-02-15 Immunos Therapeutics Ag Pharmaceutical compositions comprising hla fusion proteins
EP4380605A1 (en) 2021-08-05 2024-06-12 ImmunOs Therapeutics AG Combination medicaments comprising hla fusion proteins
WO2023021006A1 (en) 2021-08-16 2023-02-23 Universität Zürich Il-1 targeting agents for treatment of pitiyriasis rubra pilaris
WO2023021050A1 (en) 2021-08-17 2023-02-23 Athebio Ag Variants of ankyrin repeat domains
EP4137508A1 (en) 2021-08-17 2023-02-22 Athebio AG Variants of ankyrin repeat domains
JP2024532620A (en) 2021-08-30 2024-09-05 ラッセン・セラピューティクス1・インコーポレイテッド Anti-IL-11Rα antibody
WO2023036849A1 (en) 2021-09-07 2023-03-16 ETH Zürich Identifying and predicting future coronavirus variants
EP4163380A1 (en) 2021-10-08 2023-04-12 ETH Zurich Device and method for manipulation of extracellular vesicles
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
TW202334202A (en) 2021-11-16 2023-09-01 瑞士商Ac免疫有限公司 Novel molecules for therapy and diagnosis
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
AU2022413461A1 (en) 2021-12-14 2024-06-06 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
CR20240246A (en) 2021-12-20 2024-07-19 Hoffmann La Roche Agonistic ltbr antibodies and bispecific antibodies comprising them
WO2023117987A1 (en) 2021-12-21 2023-06-29 Universität Zürich Adenoviral vectors
MX2024009948A (en) 2022-02-16 2024-08-22 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof.
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
WO2023186756A1 (en) 2022-03-28 2023-10-05 F. Hoffmann-La Roche Ag Interferon gamma variants and antigen binding molecules comprising these
WO2023195515A1 (en) * 2022-04-06 2023-10-12 独立行政法人国立高等専門学校機構 Method for constructing mixed population containing nucleic acids having different sequence repeats and different numbers of repetitions
AU2023250038A1 (en) 2022-04-08 2024-11-14 Ac Immune Sa Anti-tdp-43 binding molecules
EP4260907A1 (en) 2022-04-11 2023-10-18 Universität Zürich Agents for treatment of endometriosis and other benign gynecological neoplasms
WO2023217904A1 (en) 2022-05-10 2023-11-16 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
WO2024002914A1 (en) 2022-06-27 2024-01-04 Charité-Universitätsmedizin Berlin Prediction of, and composition to improve, tendon healing
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
WO2024037743A1 (en) 2022-08-16 2024-02-22 Athebio Ag Variants of ankyrin repeat domains
WO2023194628A2 (en) 2022-08-16 2023-10-12 Athebio Ag Variants of ankyrin repeat domains
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024044770A1 (en) 2022-08-26 2024-02-29 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer
WO2024047114A1 (en) 2022-08-31 2024-03-07 Universität Zürich Adenoviral-based in situ delivery of bispecific t cell engagers
WO2024056862A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
US20240228620A1 (en) 2022-10-06 2024-07-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
WO2024074706A1 (en) 2022-10-07 2024-04-11 Universität Zürich Paracrine adenoviral delivery of biomolecules
WO2024094741A1 (en) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Combination therapy with anti-cd19/anti-cd28 bispecific antibody
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
WO2024118771A1 (en) 2022-11-30 2024-06-06 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
WO2024133013A1 (en) 2022-12-19 2024-06-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. Means and methods to target endogenous condensates
WO2024148241A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. Anti-il-18bp antibodies
WO2024148240A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE
WO2024165671A1 (en) 2023-02-08 2024-08-15 Immunos Therapeutics Ag FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
EP4428159A1 (en) 2023-03-10 2024-09-11 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Melanoma targeting human antibodies and therapeutic uses thereof
EP4428158A1 (en) 2023-03-10 2024-09-11 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Lung cancer targeting human antibodies and therapeutic uses thereof
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01501755A (en) * 1986-11-04 1989-06-22 シントロ コーポレイション Construction of synthetic DNA and its use in the synthesis of large polypeptides
DE768377T1 (en) 1988-09-02 1998-01-02 Dyax Corp Production and selection of recombinant proteins with different binding sites
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
EP0656950B1 (en) 1992-08-21 1998-11-04 Biogen, Inc. Tat-derived transport polypeptides
EP0781331B1 (en) 1994-08-20 2008-09-03 Gendaq Limited Improvements in or relating to binding proteins for recognition of dna
DE19631106A1 (en) 1996-08-01 1998-02-05 Heinz Peter Brandstetter Stator plate or stator element
US5932440A (en) 1996-08-16 1999-08-03 Life Technologies, Inc. Mammalian ribonuclease inhibitors and use thereof
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
ATE321849T1 (en) 1997-04-23 2006-04-15 Univ Zuerich METHOD FOR DETECTING NUCLEIC ACID MOLECULES CODING FOR (POLY)PEPTIDES WHICH INTERACT WITH TARGET MOLECULES
US5827692A (en) * 1997-04-24 1998-10-27 Heska Corporation Dirofilaria and Brugia ankyrin proteins, nucleic acid molecules, and uses thereof
AU750229B2 (en) * 1997-07-18 2002-07-11 Yale University Structure of the ankyrin binding domain of a alpha-Na,K-ATPase
DK1137812T3 (en) 1998-12-02 2007-05-21 Adnexus Therapeutics Inc DNA-protein fusions and uses thereof
ATE439592T1 (en) * 1998-12-10 2009-08-15 Bristol Myers Squibb Co PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS AND OTHER BINDING PROTEINS
US20020042094A1 (en) * 1999-12-15 2002-04-11 Venezia Domenick R. RING finger protein zapop2
EP1266004A2 (en) 2000-02-17 2002-12-18 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
AU2001259471A1 (en) 2000-05-05 2001-11-20 Maxygen, Inc. Evolution of plant disease response pathways to enable the development of plant based biological sensors and to develop novel disease resistance strategies
US6750057B2 (en) * 2000-06-29 2004-06-15 University Of Florida Ubiquitin ligase

Also Published As

Publication number Publication date
US9657287B2 (en) 2017-05-23
US20090082274A1 (en) 2009-03-26
US7417130B2 (en) 2008-08-26
ATE448301T1 (en) 2009-11-15
EP1332209B1 (en) 2009-11-11
WO2002020565A2 (en) 2002-03-14
JP2013179942A (en) 2013-09-12
DE60140474D1 (en) 2009-12-24
US8110653B2 (en) 2012-02-07
US20120142611A1 (en) 2012-06-07
US20040132028A1 (en) 2004-07-08
ES2335861T3 (en) 2010-04-06
US20150275201A1 (en) 2015-10-01
CA2421447C (en) 2012-05-08
DK1332209T3 (en) 2010-03-29
JP5291279B2 (en) 2013-09-18
WO2002020565A3 (en) 2002-11-07
EP1332209A2 (en) 2003-08-06
CA2421447A1 (en) 2002-03-14
US9006389B2 (en) 2015-04-14
JP2016053031A (en) 2016-04-14
EP2149604A1 (en) 2010-02-03
JP2004508033A (en) 2004-03-18

Similar Documents

Publication Publication Date Title
AU2002218166A1 (en) Collections of repeat proteins comprising repeat modules
WO2001004314A3 (en) Nucleic acid molecules and proteins associated with sterol synthesis and metabolism
ATE368688T1 (en) PEPTIDES, THEIR PRODUCTION AND USE FOR BINDING IMMUNOGLOBULINS
WO2002074807A3 (en) Chimpanzee erythropoietin (chepo) - immunoadhesins
WO1999054349A3 (en) Dermatophagoides nucleic acid molecules, proteins and uses thereof
DK1005532T3 (en) Isolated nucleic acid molecules encoding SSX family members and their applications
AU2002328909A1 (en) Nucleic acid molecules encoding proteins essential for plant growth
WO2001096535A3 (en) Nucleic acid coding for a bonding site of a protein kinase of the mitogenic signalling cascade of a glycolysis-catalysing enzyme
AU2002256019A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU1323200A (en) Isolated nucleic acid molecules which encode scp proteins, and uses thereof
WO2002063013A3 (en) Human acid phosphatase gene
ZA9811211B (en) Isolated nucleic acid molecules which encode TAGE molecules, and useS thereof.
WO2002070712A3 (en) Chitin deacetylase and method for producing the same
WO2005000882A3 (en) Dna fragments and proteins encoded by said dna isolated from bifidobacteria
AU2002258618A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2002307004A1 (en) Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof
AU2002228599A1 (en) Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof
AU2002258629A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2002314731A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2002311750A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2002303180A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
ATE397060T1 (en) NUCLEIC ACID MOLECULES ENCODING A PROTEIN WHICH INTERACTS WITH A SER/THR AKT KINASE
AU2002243460A1 (en) Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof
WO2005046577A3 (en) Human prostaglandin ep1 receptor variants and methods of using same
WO2002072142A3 (en) Modulation of a balance between the gut mucosal immune system and the intestinal microflora